

PCT
JC03 Rec'd PCT/PTO 26 SEP 2005

I hereby certify that this correspondence is being deposited with the United States Postal Service on the date set forth below as First Class Mail in an envelope addressed to: Commissioner for Patents, P O Box 1450, Alexandria, VA 22313-1450.

Date of Signature and Deposit: September 22, 2005


Sara D. Vinarov

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Robin L. Polt
Edward J. Bilsky

Date: September 22, 2005

Serial No.: 10/540,443

Art Unit:

Filed: 06/22/2005

Examiner:

For: GLYCOSOLATED ENKEPHALIN AGENTS

Docket: 920214.00005

INFORMATION DISCLOSURE STATEMENT


Commissioner for Patents
P O Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed is a completed Form PTO-1449 listing documents that the applicants in the above-identified application wish to bring to the attention of the Examiner for consideration in connection with the examination on the merits of this application.


No fee is believed due in connection with this submission. However, if a fee is due, please charge the fee to Deposit Account No. 17-0055.

Respectfully submitted,



Sara D. Vinarov
Reg. No. 48,524
Attorney for Applicants
QUARLES & BRADY LLP
P.O. Box 2113
Madison, WI 53701-2113

TEL (608) 251-5000
FAX (608) 251-9166



(Use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

Application Number	10/540,443
Filing Date	06/22/2005
First Named Inventor	Robin L. Polt
Art Unit	
Examiner Name	
Attorney Docket Number	920214.00005

[illegible][illegible]

**Examiner
Signature**

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450.. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/540,443
		Filing Date	06/22/2005
		First Named Inventor	Robin L. Polt
		Art Unit	
		Examiner Name	
Sheet 2 of 2	Attorney Docket Number 920214.00005		

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Bilsky, E.J., et al., "Enkephalin Glycopeptide Analogues Produce Analgesia with Reduced Dependence Liability, Journal of Medicinal Chemistry 43:2586-2590 (2000)	
		Egleton, R.D., et al., "Improved bioavailability to the brain of glycosylated Met-enkephalin analogs," Brain Research 881:37-46 (2000)	
		Egleton, R.D., et al., "Improved Blood-Brain Barrier Penetration and Enhanced Analgesia of an Opioid Peptide by Glycosylation," The Journal of Pharmacology and Experimental Therapeutics 299:967-972 (2001)	
		Elmagbari, N., et al., "Antinociceptive Structure Activity Studies With Novel Opioid Glycopeptides," FASEB J. Vol. 15:A915 (2001) Annual Mtg. of the Federation of American Soc. for Exper. Biol. on Exper. Biology 2001 Orlando FL Abstract 711	
		Horvat, S., et al., "A New Utility of O-Glycosylpseudoureas for Synthesis of Glcopeptides and (1-6)-Disaccharides," Synthesis 3:209-211 (1986)	
		Mitchell, S.A., et al., "Solid-Phase Synthesis of O-Linked Glycopeptide Analogues of Enkephalin," J. Org. Chem. 66:2327-2342 (2001)	
		Palian, M.M., et al., "Glycopeptide-membrane Interactions: Glycosyl Enkephalin Analogues Adopt Turn Conformations by NMR and CD in Amphipathic Media," J. Am. Chem. Soc. 125:5823-5831 (2003)	
		Polt, R., et al., "Glycopeptide enkephalin analogues produce analgesia in mice: Evidence for penetration of the blood-brain barrier," Prod. Natl. Acad. Sci. USA 91:7114-7118 (1994)	
		Polt, R., et al., "Glycosylated Enkephalins Penetrate the Blood-Brain Barrier Adsorptive Endocytosis-Analgesia Superior to Morphine," Abstract 225th ACS Nat'l Meeting, New Orleans, LA 2003 Abstract 256	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.